trending Market Intelligence /marketintelligence/en/news-insights/trending/e7by0OiJu8_imGFezBi3VQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Valeant's eye drops rejected by US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Valeant's eye drops rejected by US FDA

The U.S. Food and Drug Administration rejected Valeant Pharmaceuticals International Inc.'s investigative eye drops for patients with open angle glaucoma or ocular hypertension.

The complete response letter for latanoprostene bunod ophthalmic solution only refers to a current good manufacturing practice inspection at a Bausch & Lomb facility in Tampa, Fla.

The letter did not identify any efficacy or safety issues with the application for the eye drops or additional clinical trials needed for the approval of the application.

Valeant said it will work closely with the agency to determine the suitable next steps for the application.